ArticleBlood cancer journal2022

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS).

Andrew M Brunner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.